BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Plerixafor readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Plerixafor\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05343572-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Plerixafor: Phase 1 readout est. (NCT05343572)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Bone Marrow Derived Stem Cells Mo
 bilization for Treatment of Abnormal Endometrium\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 plerixafor#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05343572
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06414889-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Plerixafor: Phase 1 readout est. (NCT06414889)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Protocol Title: Safety and Feasib
 ility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Aphere
 sis in Participants With RUNX1 Familial Platelet Disorder\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/plerixafor#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06414889
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03664830-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Plerixafor: Phase 1 readout est. (NCT03664830)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Safety of Blood Stem Cell Mobiliz
 ation With Plerixafor in Patients With Sickle Cell Disease\nEstimated prim
 ary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/plerixafor#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03664830
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05470491-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT05470491)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: Trial of Allogeneic Reduced-Int
 ensity\, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Tran
 splantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With 
 Cyclophosphamide\, Bortezomib and Maraviroc for Hematologic Malignancies .
 ..\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/plerixafor#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05470491
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341022-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT07341022)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: STEM CELL MOBILIZATION WITH HIG
 H-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/plerixafor#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07341022
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05088356-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Plerixafor: Phase 1 readout est. (NCT05088356)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Reduced Intensity Allogeneic HCT 
 in Advanced Hematologic Malignancies w/T-Cell Depleted Graft\nEstimated pr
 imary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/plerixafor#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05088356
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158828-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT06158828)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: Pilot Study of Memory-like Natu
 ral Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Tran
 splant in AML\nEstimated primary completion: 15 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/plerixafor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06158828
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585136-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Plerixafor: Phase 1 readout est. (NCT07585136)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Stem Cell Mobilization and Aphere
 sis for Life-threatening Blood Disorders\nEstimated primary completion: 1 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/plerix
 afor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07585136
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506461-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Plerixafor: Phase 1 readout est. (NCT06506461)
DESCRIPTION:Plerixafor\, phase 1.\nStudy: Gene Editing For Sickle Cell Dise
 ase\nEstimated primary completion: December 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/plerixafor#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06506461
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06872333-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Plerixafor: Phase 2 readout est. (NCT06872333)
DESCRIPTION:Plerixafor\, phase 2.\nStudy: Allo HSCT for High Risk Hemoglobi
 nopathies\nEstimated primary completion: 1 June 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/plerixafor#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06872333
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02015013-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Plerixafor: Phase 2 readout est. (NCT02015013)
DESCRIPTION:Plerixafor\, phase 2.\nStudy: Hematopoietic Stem Cell Mobilizat
 ion in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for th
 e Study of T Cell Maturation and Trafficking in Murine Models\nEstimated p
 rimary completion: 31 October 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/plerixafor#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT02015013
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775313-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT07775313)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: Base-Edited Hematopoietic Stem/
 Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM\nEstimated primar
 y completion: 31 December 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/plerixafor#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07775313
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Plerixafor: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Plerixafor\, phase 2.\nStudy: Testing an Experimental Approach 
 to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstimated
  primary completion: 6 November 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/plerixafor#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06325709-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT06325709)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: Base Editing for Mutation Repai
 r in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomat
 ous Disease\nEstimated primary completion: 31 December 2032. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/plerixafor#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06325709
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06851767-3206@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Plerixafor: Phase 1/2 readout est. (NCT06851767)
DESCRIPTION:Plerixafor\, phase 1/2.\nStudy: Base-Edited Hematopoietic Stem/
 Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy\nEs
 timated primary completion: 31 December 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/plerixafor#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06851767
URL:https://assetmemo.bio/drug/plerixafor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
